PCIB PCI Biotech Holding ASA

Flaggemelding relatert til PCIB

Flaggemelding relatert til PCIB

Myrlid AS har i dag, 20. januar 2023, solgt 450 000 aksjer i PCI Biotech Holding ASA ("Selskapet"). Som følge av salget innehar Myrlid AS etter dette totalt 1 450 000 aksjer og stemmer i Selskapet direkte, samt eierskap til ytterligere 400 000 aksjer gjennom sitt 50 % eierskap i Jandersen Kapital AS, totalt sett tilsvarer dette ca. 4,95 % av aksjene og stemmene i Selskapet.

 



EN
20/01/2023

Underlying

PCIBPCI Biotech Holding ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PCI Biotech Holding ASA

 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech half-year interim 2025 report

PCI Biotech half-year interim 2025 report Oslo (Norway), 29 August 2025 – PCI Biotech (OSE: PCIB), today announces its half-yearly 2025 interim report. Please find enclosed the interim report and presentation. Highlights review OperationsPCI Biotech decided on 18th August 2025 to discontinue further development of the PCL technology. The decision was primarily based on, as described in a press release the same day, insufficient progress towards the 2025 goal of demonstrating improved net yield at mini benchtop bioreactor scale. Achieving successful results at this scale was a critical ris...

August 29, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech: Invitation to first half 2025 results presentation and co...

PCI Biotech: Invitation to first half 2025 results presentation and corporate update Oslo, Norway, 26 August 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2025 interim report on Friday, 29 August 2025, 08:30am – 09:00am CET (local time).  The presentation will be held in Norwegian as a live webcast available through There will be a Q&A session at the end of the presentation. Please submit questions to prior to the webcast. It will be possible to post written questions through the webcast console during the session. The interim report and ...

August 26, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

Flaggemelding

Flaggemelding Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag solgt 2 000 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS ingen aksjer i PCI Biotech Holding ASA.

August 22, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

Flaggemelding

Flaggemelding Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag kjøpt 240 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS 2 000 000 aksjer, noe som utgjør 5,36% av aksjene i PCI Biotech Holding ASA.

August 22, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech announces discontinuation of development of the PCL techno...

PCI Biotech announces discontinuation of development of the PCL technology and evaluation of future operations Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector manufacturing.  Today’s decision is primarily based on the insufficient progress towards the 2025 goal of demonstrating improved yield in mini benchtop bioreactors. Achieving successful end-to-end results in small bioreactors is a critical risk-reducing milestone for further development. Fol...

August 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch